Riptide Bioscience Announces Cooperative Research and Development Agreement with the National Cancer Institute
October 3, 2016
SAN FRANCISCO, CA. – Henry Lopez, Executive Vice President of Riptide Bioscience, Inc., today announced the execution of a Cooperative Research and Development Agreement (NCI CRADA #03045) with the National Cancer Institute (NCI), part of the National Institutes of Health. The agreement carries a three-year term and is entitled, Evaluation of Riptide Bioscience's Proprietary Peptide RP-182 in Preclinical Studies for the Treatment of Pancreatic Cancer. Research under the CRADA is intended to generate data to support an Investigational New Drug filing of this agent with the FDA.
Pancreatic cancer is among the most lethal of all diseases; 90% of patients die within one year of diagnosis. Even following surgical removal of the primary tumor, long-term survival rates are poor, with tumors recurring in virtually all patients. Modern chemotherapy approaches have to date yielded only marginal improvements of several months in median survival.
Lopez stated, "We're delighted to finalize this agreement with NCI and believe it is an important affirmation of the strength of Riptide's research program. Our development team has already been working closely with NCI for the last several years, and NCI scientists have had an opportunity to test RP-182 in transgenic models of pancreatic tumors, with significant success. RP-182 strongly complements the effectiveness of chemotherapies such as gemcitabine, substantially arresting tumor growth and extending survival."
Lopez continued, "We believe that RP-182 will prove to be complementary to both conventional chemotherapies and emerging immunotherapies. RP-182 alters the balance of cell populations in the tumor microenvironment so as to become tumor-inhibiting rather than tumor-promoting. We think this approach has real potential to become the 'third leg' of a therapeutic tripod that currently includes chemotherapy and immunotherapy."
The National Cancer Institute's team on the RP-182 project comes from the Thoracic and Gastrointestinal Oncology Branch, in the Center for Cancer Research, Bethesda, Maryland. The NCI team is headed by Dr. Udo Rudloff (MD, PhD), a physician scientist with both research and patient-care responsibilities.
Dr. Rudloff stated, "The anti-cancer efficacy of RP-182 in combination with chemotherapy compares favorably to previous treatment modalities which were tested in similar transgenic animal models of pancreatic cancer, and which are currently either in clinical trials or have received regulatory approval for the treatment of pancreatic cancer. Our expectation and hope is to make such promising therapeutics available to patients afflicted by pancreatic cancer."
Lopez commented, "We are particularly encouraged that the participation of the Thoracic and Gastrointestinal Oncology Branch may ease the transition from preclinical evaluation to clinical trials. Taking advantage of certain structural features of naturally occurring peptides, RP-182 has shown no toxicity at concentrations several times that of the therapeutically effective dose. We are eager to confirm its safety in humans as the next step toward extending the lives and improving the health of pancreatic cancer patients."
Riptide Bioscience, Inc., with laboratories in Vallejo, California, maintains an intensive program of research into peptide-based therapeutics. Contact: email@example.com
Riptide Bioscience President to Address AACR Conference
January 10, 2016
SAN FRANCISCO, CA. – Dr. George R. Martin, President of Riptide Bioscience, delivered an invited presentation to the American Association for Cancer Research (AACR) Special Conference on "The Function of Tumor Microenvironment in Cancer Progression," held in San Diego, California, on January 7 - 10, 2016.
Dr. Martin's presentation was entitled "Synthetic peptides suppress M2 macrophages and synergize with chemotherapy in prostate and breast cancer models." It summarized the body of in vitro and in vivo research on certain amphipathic peptides currently understood to restore the balance between canonically and alternatively activated macrophages in solid organ tumors.
Dr. Martin presented the findings of repeated in vivo studies that such peptides show synergy with Gemcitabine, Docetaxel, and other chemotherapeutic agents, reducing tumor growth and extending survival in a number of well-characterized animal models.
Dr. Martin is the former Scientific Director of the National Institute on Aging, and former Chief Scientific Officer of Fibrogen, Inc. (NASDAQ: FGEN). The invention of Matrigel and the discovery of laminin, lysyl oxidase, and procollagen were products of Dr. Martin's NIH laboratory.
This was the second consecutive year for which an AACR Special Conference was scheduled focusing on the tumor microenvironment, increasingly understood to play a significant role in tumor growth and metastasis.
Riptide Bioscience, with laboratories in Vallejo, California, maintains an intensive program of research into peptide compounds with potent antimicrobial and immunomodulatory activity. Contact: firstname.lastname@example.org
Thompson Announces $1.5 Million Defense Department Grant for Riptide Bioscience
October 9, 2015
WASHINGTON D.C. – U.S. Rep. Mike Thompson (CA-5) today announced a $1.5 million Defense Department grant for Riptide Bioscience, Inc. Riptide Bioscience is based in Vallejo on Mare Island. The grant, part of the US Army Medical Research Acquisition Activity (USAMRAA), will go towards a research project titled the “Evaluation of Novel Antimicrobial Peptides as Topical Anti-Infectives with Broad Spectrum Activity Against Combat-Related Bacterial and Fungal Wound Infections.”
"For several years, Riptide has been doing cutting-edge medical research right here in Vallejo," said Thompson. "Their research into wound-healing applications will provide great benefits to those in our military as well as the general population. Some 75 percent of recent war injuries are the result of ballistic wounds, and our Riptide is finding new and better methods to fight infections that result from those wounds. Their work will benefit our local economy, and I'm proud to support this kind of leading medical science emerging from our district."
Henry Lopez, Executive Vice President of Riptide, said, "The research funded by this grant has huge potential to improve outcomes for war-wounded servicemen and women, and also civilian patients suffering from everyday wounds and trauma."
Lopez continued, "This grant was one of only five funded in a tremendously competitive process involving some 280 applications from top research institutions across the nation. So we see it as powerful affirmation for the peptide-based therapeutics Riptide is developing."
L. Edward Clemens, Principal Investigator on the Defense Department project, added, "As exciting as it is to improve the medical science behind wound healing, the work done here may have even wider application. One of the biggest challenges in our health system is the growing resistance of bacteria to conventional antibiotics. As those drugs are more widely used, bacteria mutate around the metabolic pathways the drugs use to kill germs. This is a crisis in the making. Some estimates suggest that in just a few years, antimicrobial resistance will lead to more deaths than cancer and diabetes combined."
"But Riptide's agents don't work through the usual pathways," Clemens continued. They kill bacteria in ways much harder to mutate around. We expect these drugs to be a big part of the medical armament against the germs of the future."
Riptide Bioscience’s research involves the development of Designed Host Defense Peptides (dHDPs). HDPs are small molecular weight proteins that fight against pathogenic bacteria, viruses, protozoa, and fungi.
Congressman Mike Thompson is proud to represent California’s 5th Congressional District, which includes all or part of Contra Costa, Lake, Napa, Solano and Sonoma Counties. He is a senior member of the House Ways and Means Committee. Rep. Thompson is also a member of the fiscally conservative Blue Dog Coalition and chairs the bipartisan, bicameral Congressional Wine Caucus.
Riptide Bioscience, Inc. Begins Research Under $222,000 NEI Grant
October 1, 2014
SAN FRANCISCO, CA. – Charles Garvin, CEO of Riptide Bioscience, Inc., announced Riptide's initiation of work under a $222,179 Small Business Innovation Research federal grant. The grant, from the National Eye Institute (NEI), will go towards a research project titled Designed Host Defense Peptides for the Treatment of Bacterial Keratitis.
“Our firm, Riptide Bioscience, has been developing peptides that have remarkable antibacterial activity, and also fight the inflammation that accompanies many serious illnesses,” said Garvin. “Keratitis is one of the conditions where a real concern is the development of bacterial resistance to the most common drugs. But bacteria can’t easily develop resistance to these peptides, which are proteins derived from naturally occurring defense mechanisms. The promise here is to develop a whole class of therapeutics that trump bacterial resistance and can be used against a very wide range of diseases. With new resistant strains arising every day, the need is urgent.” Bacterial keratitis is an infection of the cornea, the clear, round dome covering the eye's iris and pupil, that causes pain, reduced vision, light sensitivity and tearing or discharge from your eye. Resulting from infection from contact lens use or from injury to the eye, bacterial keratitis usually develops very quickly, and if left untreated, can cause blindness.
Bacterial keratitis afflicts 30,000 patients in the United States every year.
Riptide Bioscience's goal is to bring Designed Host Defense Peptides (dHDPs) to clinical practice. dHPDs are small molecular weight proteins that fight against bacteria, viruses, and fungi, and can be used for the topical treatment of keratitis.